Human evidence record · Modified GRF(1-29) / 'CJC without DAC'
D-Ala2 GHRH(1-29) pharmacokinetics in normal men
D-Ala2 substitution reduced metabolic clearance and increased disappearance half-time from 4.3 to 6.7 minutes.
Quick read
Human evidence record
What this study tells us
This was a human pharmacology or physiology study. It can show what the compound does to measured biological signals, but it may not establish a meaningful clinical benefit.
Who was studied?
Normal men
How many?
n=10
What happened?
D-Ala2 substitution reduced metabolic clearance and increased disappearance half-time from 4.3 to 6.7 minutes.
What stops us overclaiming?
This is a single-substitution GHRH analogue, not the four-substitution marketplace Modified GRF(1-29); it is mechanistic context only.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
D-Ala2 substitution reduced metabolic clearance and increased disappearance half-time from 4.3 to 6.7 minutes.
Study details
Study designHuman pharmacokinetic comparative study
PopulationNormal men
Sample size10
RouteIntravenous infusion
Regimen / exposureD-Ala2-GHRH(1-29)-NH2 at 25 ng/kg/min for 90 minutes
Duration90 minutes + washout sampling
ComparatorNative GHRH(1-29)-NH2
Primary endpoint / questionMetabolic clearance and half-time
Safety resultNo major adverse effects highlighted in the abstract.
Key limitationsThis is a single-substitution GHRH analogue, not the four-substitution marketplace Modified GRF(1-29); it is mechanistic context only.
Registry / identifierPMID 7962295